The purpose of this Cancer Center Support Grant is to reduce cancer incidence, morbidity and mortality by providing an organizational structure and administration which maximizes the quality and interdisciplinary nature of competitive funded cancer research activities at the City of Hope. The core grant provides the mechanisms for continuous planning and evaluation of the research programs of the Center in light of new research opportunities and a broad array of technical support via state-of-the-art shared facilities.
The specific aims are to: (1) stimulate collaborative research interactions between basic science and clinical investigators and among research groups in diverse areas of investigation; (2) facilitate and enhance interdisciplinary programs in basic and clinical research; (3) develop and support core research facilities to improve the effectiveness of the Center's research programs; (4) support the development of new investigators and new programs needed to maximize the contributions of the institution as a Cancer Center. The existence of an NCI-Designated Cancer Center at the City of Hope has enhanced the commitment to cancer research by the Board of Directors and senior scientific leadership of the City of Hope. The Board recently recruited a new director experienced in Cancer Center program development and administration and continues to provide exceptional financial support for renovation and construction of clinical and basic research facilities and support of research personnel. In turn, members of the Cancer Center have competed successfully for three program project grants (gene therapy; bone marrow transplantation for hematologic malignancies; and radioimmunotherapy of cancer), a drug discovery grant for the development and delivery of anti-viral RNA as treatments for AIDS; and two consortium grants for innovative, mechanistically oriented, Phase I and Phase II cancer therapeutic trials. Six outstanding young molecular biologists were recruited to expand the gene therapy program at a basic level. Two programs in the previous grant, Tumor and Cell Biology and Virology, have been eliminated and the outstanding components in each were merged into a new program in Molecular Carcinogenesis. The existing programs in Molecular Biology, Immunology, Hematology Malignancies and Clinical and Experimental Therapeutics have been enhanced. There are two new developing programs in Cancer Control and Prevention and Breast Cancer Research. Programs are supported by 12 cores.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-15
Application #
2088551
Study Section
Cancer Centers and Research Programs Review Committee (CCRP)
Project Start
1981-07-01
Project End
2000-07-31
Budget Start
1995-08-25
Budget End
1996-07-31
Support Year
15
Fiscal Year
1995
Total Cost
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications